NERV – Minerva Neurosciences Inc.
NERV — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
6.53
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.16
EPS Last/This Y
1.69
EPS This/Next Y
-0.6
Price
4.24
Target Price
9.5
Analyst Recom
2.33
Performance Q
-30.29
Upside
-24,001.6%
Beta
-0.1
Ticker: NERV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | NERV | 4.27 | N/A | N/A | 0 |
| 2026-07-14 | NERV | 4.03 | N/A | N/A | 0 |
| 2026-07-15 | NERV | 4.32 | N/A | N/A | 0 |
| 2026-07-16 | NERV | 4.2 | N/A | N/A | 0 |
| 2026-07-17 | NERV | 4.26 | N/A | N/A | 0 |
| 2026-07-20 | NERV | 4.38 | N/A | N/A | 0 |
| 2026-07-21 | NERV | 4.47 | N/A | N/A | 0 |
| 2026-07-22 | NERV | 4.44 | N/A | N/A | 0 |
| 2026-07-23 | NERV | 4.47 | N/A | N/A | 0 |
| 2026-07-24 | NERV | 4.04 | N/A | N/A | 0 |
| 2026-07-27 | NERV | 4.21 | N/A | N/A | 0 |
| 2026-07-28 | NERV | 4.28 | N/A | N/A | 0 |
| 2026-07-29 | NERV | 4.11 | N/A | N/A | 0 |
| 2026-07-30 | NERV | 4 | N/A | N/A | 0 |
| 2026-07-31 | NERV | 3.99 | N/A | N/A | 0 |
| 2026-08-03 | NERV | 3.96 | N/A | N/A | 0 |
| 2026-08-04 | NERV | 4.04 | N/A | N/A | 0 |
| 2026-08-05 | NERV | 4.35 | N/A | N/A | 0 |
| 2026-08-06 | NERV | 4.44 | N/A | N/A | 0 |
| 2026-08-07 | NERV | 4.28 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | NERV | 4.28 | 97.7 | - | -0.20 |
| 2026-07-14 | NERV | 4.03 | 97.7 | - | -0.20 |
| 2026-07-15 | NERV | 4.32 | 97.7 | - | -0.20 |
| 2026-07-16 | NERV | 4.22 | 97.7 | - | -0.20 |
| 2026-07-17 | NERV | 4.25 | 97.7 | - | -0.20 |
| 2026-07-20 | NERV | 4.38 | 97.7 | - | -0.20 |
| 2026-07-21 | NERV | 4.47 | 97.7 | - | -0.20 |
| 2026-07-22 | NERV | 4.44 | 97.7 | - | -0.20 |
| 2026-07-23 | NERV | 4.47 | 97.7 | - | -0.20 |
| 2026-07-24 | NERV | 4.04 | 97.7 | - | -0.20 |
| 2026-07-27 | NERV | 4.20 | 97.7 | - | -0.20 |
| 2026-07-28 | NERV | 4.28 | 97.7 | - | -0.20 |
| 2026-07-29 | NERV | 4.11 | 97.7 | - | -0.20 |
| 2026-07-30 | NERV | 4.02 | 97.7 | - | -0.20 |
| 2026-07-31 | NERV | 4.00 | 97.7 | - | -0.20 |
| 2026-08-03 | NERV | 3.96 | 97.7 | - | -0.20 |
| 2026-08-04 | NERV | 3.96 | 97.7 | - | -0.20 |
| 2026-08-05 | NERV | 4.34 | 97.7 | - | -0.20 |
| 2026-08-06 | NERV | 4.42 | 97.7 | - | -0.20 |
| 2026-08-07 | NERV | 4.24 | 97.7 | - | -0.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | NERV | 0.00 | 63.62 | 5.14 |
| 2026-07-14 | NERV | 0.00 | 63.62 | 5.14 |
| 2026-07-15 | NERV | 0.00 | 63.62 | 5.14 |
| 2026-07-16 | NERV | 0.00 | 63.62 | 5.14 |
| 2026-07-17 | NERV | 0.00 | 63.62 | 5.14 |
| 2026-07-20 | NERV | 0.00 | 63.90 | 5.14 |
| 2026-07-21 | NERV | 0.00 | 63.90 | 5.14 |
| 2026-07-22 | NERV | 0.00 | 63.90 | 5.14 |
| 2026-07-23 | NERV | 0.00 | 63.90 | 5.14 |
| 2026-07-24 | NERV | 0.00 | 63.90 | 5.14 |
| 2026-07-27 | NERV | 0.00 | 65.28 | 6.53 |
| 2026-07-28 | NERV | 0.00 | 65.28 | 6.53 |
| 2026-07-29 | NERV | 0.00 | 65.28 | 6.53 |
| 2026-07-30 | NERV | 0.00 | 65.28 | 6.53 |
| 2026-07-31 | NERV | 0.00 | 65.28 | 6.53 |
| 2026-08-03 | NERV | 0.00 | 65.06 | 6.53 |
| 2026-08-04 | NERV | 0.00 | 65.06 | 6.53 |
| 2026-08-05 | NERV | 0.00 | 65.06 | 6.53 |
| 2026-08-06 | NERV | 0.00 | 65.06 | 6.53 |
| 2026-08-07 | NERV | 0.00 | 65.06 | 6.53 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.17
Avg. EPS Est. Current Quarter
-0.01
Avg. EPS Est. Next Quarter
-0.01
Insider Transactions
Institutional Transactions
65.06
Beta
-0.1
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
27
Growth Score
17
Sentiment Score
90
Actual DrawDown %
75.1
Max Drawdown 5-Year %
-91.9
Target Price
9.5
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-29.16
Average EPS Est. Cur. Y
-0.2
EPS Next Y. (Est.)
-0.8
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.77
Return on Equity vs Sector %
136.1
Return on Equity vs Industry %
152.2
EPS 1 7Days Diff
0.4
EPS 1 30Days Diff
0.4
EBIT Estimation
◆
NERV
Healthcare
$4.27
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47.8
Range 1M
38%
Sup Dist
0.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-57.9%
EPS NY
72.5%
52W%
23.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+122.5% upside
Upside
+122.5%
Quality
27
NERV — P/E HistoricalBiotechnology
Minerva Neurosciences, IncSector: Healthcare
Industry: Biotechnology
Employees: 7
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
NERV
Latest News
—
Caricamento notizie per NERV…
stock quote shares NERV – Minerva Neurosciences Inc. Stock Price stock today
news today NERV – Minerva Neurosciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NERV – Minerva Neurosciences Inc. yahoo finance google finance
stock history NERV – Minerva Neurosciences Inc. invest stock market
stock prices NERV premarket after hours
ticker NERV fair value insiders trading